GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(-16.67%)
USD 0.0
(-16.67%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -205.76 Thousand | -326.99 Thousand | -751.23 Thousand | -239.73 Thousand | -260.13 Thousand | -180.09 Thousand |
| Net Income | -1.94 Million | -1.48 Million | -9.8 Million | -541.73 Thousand | -675.07 Thousand | -816.74 Thousand |
| Depreciation & Amortization | 33.39 Thousand | 54.66 Thousand | 1275.00 | 1329.00 | 472.00 | 118.00 |
| Deferred income taxes | -33.39 Thousand | - | 2412.00 | 37.66 Thousand | -100.16 Thousand | - |
| Stock-based compensation | 1.26 Million | 509.19 Thousand | 8.13 Million | 35.5 Thousand | 68.25 Thousand | - |
| Change in working capital | 446.84 Thousand | 444.56 Thousand | 221 Thousand | 2218.00 | 12.53 Thousand | 185.2 Thousand |
| Other non-cash items | 26.66 Thousand | 152.39 Thousand | 694.7 Thousand | 225.28 Thousand | 433.84 Thousand | 451.32 Thousand |
| Investing Cash Flow | - | - | - | -1782.00 | - | -1412.00 |
| Investments in PPE | - | - | - | -1782.00 | - | -1412.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | -1412.00 |
| Financing Cash Flow | 199.39 Thousand | 327.4 Thousand | 675.75 Thousand | 222.5 Thousand | 269 Thousand | 259 Thousand |
| Debt repayment | -55 Thousand | - | -95 Thousand | -222 Thousand | -269 Thousand | -259 Thousand |
| Dividends payments | - | - | - | - | -1.6 Million | - |
| Common Stock Repurchased | - | - | - | - | -269 Thousand | - |
| Common Stock Issuance | 145.5 Thousand | 5000.00 | 580.75 Thousand | 500.00 | 340.26 Thousand | 109.18 Thousand |
| Other Financing Activities | -1105.00 | 322.4 Thousand | 580.75 Thousand | 444 Thousand | 466.74 Thousand | 149.82 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 435.08 Thousand | 432.42 Thousand | 203.53 Thousand | -6600.00 | 8529.00 | 188.08 Thousand |
| Inventory | - | - | - | 36.00 | -36.3 Thousand | -3815.00 |
| Other working capital | 11.76 Thousand | 12.13 Thousand | 17.47 Thousand | 8782.00 | 40.3 Thousand | 939.00 |
| Cash at beginning of period | 6365.00 | 5960.00 | 81.44 Thousand | 100.45 Thousand | 91.59 Thousand | 14.1 Thousand |
| Cash at end of period | - | 6365.00 | 5960.00 | 81.44 Thousand | 100.45 Thousand | 91.59 Thousand |
| Capital Expenditure | - | - | - | -1782.00 | - | -1412.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -6365.00 | 405.00 | -75.48 Thousand | -19.01 Thousand | 8862.00 | 77.49 Thousand |
| Free Cash Flow | -205.76 Thousand | -326.99 Thousand | -751.23 Thousand | -241.51 Thousand | -260.13 Thousand | -181.5 Thousand |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -197.66 Thousand | -174.96 Thousand | -163.75 Thousand | -350.57 Thousand | -1.94 Million | -1.28 Million |
| Depreciation & Amortization | 3715.00 | - | 5262.00 | 24.04 Thousand | 33.39 Thousand | - |
| Deferred income taxes | - | - | -38.01 Thousand | 9343.00 | -33.39 Thousand | - |
| Stock-based compensation | -13.29 Thousand | 23.55 Thousand | 25 Thousand | 108.51 Thousand | 1.26 Million | 1.12 Million |
| Change in working capital | 186.84 Thousand | 132.03 Thousand | 90.68 Thousand | 159.75 Thousand | 446.84 Thousand | 115.02 Thousand |
| Other non-cash items | 3715.00 | 30.53 Thousand | 38.01 Thousand | -23.77 Thousand | 26.66 Thousand | 1469.00 |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 20.44 Thousand | 12.38 Thousand | 42.8 Thousand | 72.69 Thousand | 199.39 Thousand | 40 Thousand |
| Debt repayment | -25 Thousand | - | -25 Thousand | -40 Thousand | -55 Thousand | -15 Thousand |
| Dividends payments | -32.34 Thousand | - | -32.34 Thousand | -96.25 Thousand | - | - |
| Common Stock Repurchased | - | - | 32.34 Thousand | - | - | - |
| Common Stock Issuance | -926.33 Thousand | 17.5 Thousand | 17.5 Thousand | 32 Thousand | 145.5 Thousand | 27.5 Thousand |
| Other Financing Activities | -4555.00 | -5116.00 | 17.95 Thousand | 695.00 | -1105.00 | -2500.00 |
| Accounts receivables | -692.65 Thousand | - | - | - | - | - |
| Accounts payables | 101.08 Thousand | 131.64 Thousand | 88.06 Thousand | 156.58 Thousand | 435.08 Thousand | 113.24 Thousand |
| Inventory | -2412.00 | - | - | - | - | - |
| Other working capital | 85.75 Thousand | 132.03 Thousand | 2627.00 | 3172.00 | 11.76 Thousand | 1777.00 |
| Cash at beginning of period | 20.47 Thousand | - | - | - | 6365.00 | 176.00 |
| Cash at end of period | 41.00 | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -20.43 Thousand | - | - | - | -6365.00 | -176.00 |
| Free Cash Flow | -20.4 Thousand | -12.38 Thousand | -42.8 Thousand | -72.69 Thousand | -205.76 Thousand | -40.17 Thousand |
NCL
PCAR
300380
3648
BETRF
AUROPHARMA